JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Allowed: BRAF V600 mutation

Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.

Allowed: MLH1 MSI-H

CRC [MSI-H]

Must have received: platinum-based chemotherapy — NSCLC, HNSCC

NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion in the study. HNSCC: eligible for platinum therapy and received platinum-based therapy prior to inclusion in this study.

Must have received: BRAF inhibitor — Melanoma with known BRAFv600 mutation

Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.

Must have received: checkpoint inhibitor — NSCLC, HNSCC, melanoma, RCC, and UC (Parts A2 and B)

previously-treated (≥ 1 line of prior anticancer therapy) participants with select tumor types (NSCLC, HNSCC, melanomas, RCC, and UC) who have progressed on/after prior CPI therapy

Cannot have received: IFNα therapy

Receipt of prior IFNα therapy

Cannot have received: anticancer therapy

Exception: within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug

Received any anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug

Cannot have received: radiotherapy

Exception: within 2 weeks of the first dose of study drug or have had a history of radiation pneumonitis

Received prior radiotherapy within 2 weeks of the first dose of study drug or have had a history of radiation pneumonitis